Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours

NCT03697304 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

211

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasm Metastasis
Advanced Tumors
Metastatic Solid Tumors

Interventions

DRUG: Ezabenlimab
DRUG: BI 754111
DRUG: BI 836880

Sponsor

Boehringer Ingelheim